AstraZeneca signs $555mn AI deal to develop gene-editing therapies — Pharmaceutical company is latest to invest in artificial intelligence to speed drug development — AstraZeneca has signed a $555mn deal with a San Francisco-based biotech business that specialises in artificial intelligence …
Posted from: this blog via Microsoft Power Automate.